CWI1-2

SKU: orb1944844

Description

CWI1-2 is a potent and selective small molecule inhibitor of IGF2BP2, disrupting its interaction with m6A-modified mRNAs. This compound exhibits anti-leukemic effects by promoting apoptosis and differentiation in cancer cells, supporting its use in oncology research for studying RNA-binding protein function in both in vitro and in vivo models.

Research Area

Cell Biology

Key Properties

• CAS Number: 2408590-36-1
• MW: 519.77
• Purity: 98.27% (May vary between batches)
• Formula: C₂₂H₁₇Cl₃N₆O₃
• SMILES: ClC1=CC=C(O)C(C=NN=C(NN=CC2=CC(Cl)=CC=C2O)NN=CC3=CC(Cl)=CC=C3O)=C1
• Target: Apoptosis
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.85 mM);DMSO:90 mg/mL (173.15 mM)

Bioactivity

• In Vivo:
  Administered intravenously at 5 mg/kg once daily for 7-10 days, CWI1-2 significantly delays the onset of leukemia and extends the survival time in BMT (bone marrow transplantation) recipient B6.SJL (CD45.1) mice, with no apparent impact on body weight.
  Read more...
• In Vitro:
  CWI1-2 demonstrates excellent anti-leukemia efficacy in a concentration range of 0-1 μM for 24 hours.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CWI1-2, CWI12, Apoptosis

Compound Identifiers

PubChem CID

139267585